sunresin(300487)2025-04-23 15:36Financial Performance - In 2024, the company achieved operating revenue of 2.55 billion, a year-on-year increase of 2.6% [2] - The net profit attributable to shareholders reached 787 million, up 9.8%, with a profit growth rate exceeding revenue growth by 7.2 percentage points [2] - Excluding the salt lake lithium extraction project, the core business revenue was 2.46 billion, a 25% increase, accounting for 96.1% of total revenue [2] - The comprehensive gross profit margin for 2024 was 49.5%, remaining stable compared to the previous year [2] Q1 2025 Performance - In Q1 2025, the company reported revenue of 577 million, a decrease of 8% year-on-year, but net profit attributable to shareholders increased by 1.93% [2][3] - Excluding the salt lake lithium project, core business revenue in Q1 2025 was 577 million, reflecting a 9% year-on-year growth [3] Project Revenue Recognition - In Q1 2024, the company recognized approximately 99 million in revenue from the Guotou Luokai project [4] - Revenue from ongoing salt lake lithium projects will be recognized based on project progress and fulfillment of contractual obligations [4] Life Sciences Sector - The company has expanded production capacity in the life sciences sector, achieving capacities of 120 tons and 70,000 liters for solid-phase carriers and agarose/dextran respectively [5] - Plans are in place to establish a new GMP-grade production facility and an independent life sciences park to enhance product quality and stability [5] Domestic and International Market Strategy - The company achieved overseas sales revenue of 655 million, a significant increase of 45.1% year-on-year, outpacing domestic growth [10] - The internationalization strategy has been a key competitive advantage, with a focus on expanding into North America, Europe, Asia, South America, and Africa [10] - In 2024, the company established a wholly-owned subsidiary in the U.S. and set up storage units in North America and Europe to enhance operational efficiency [10] Technological Advancements - The company has achieved effective domestic substitution in various fields, including cephalosporin production and gallium extraction, leveraging proprietary adsorption technology [6] - The demand for solid-phase synthesis carriers is driven by the significant growth in GLP-1 peptide drug sales, maintaining a high market share [7] - The company is actively innovating in energy-saving and environmental protection technologies, with stable sales trends in CO2 capture and wastewater treatment products [9]